The FDA has declared an end to the shortage of a popular obesity drug. The implications for consumers are complicated.
President-elect Donald Trump has asked the Supreme Court to delay implementation of the law banning TikTok. Western officials say North Korean soldiers are dying in high numbers along the Ukrainian ...
By aiding weight loss, Zepbound can improve symptoms of obstructive sleep apnea (OSA) in people with obesity — but CPAP ...
Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 500.39% and ...
A specific class of anti-inflammatory drugs can help children avoid a debilitating complication of Crohn's disease, a new study shows.
The U.S. Food and Drug Administration (FDA) has proposed a new rule to require standardized testing of talc-containing ...
Patients taking a compounded alternative to Eli Lilly's weight loss drug Zepbound will need to transition to the name-brand ...
The growing popularity of GLP-1 receptor agonists—including Ozempic and Wegovy from Novo Nordisk, and Mounjaro and Zepbound ...
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Ozempic, Wegovy, and other GLP-1 receptor agonists have become a game-changer in obesity treatment, but their high ...
Eli Lilly and Novo Nordisk are the two biggest names in the pharmaceutical sector, but I see one as the clear-cut winner for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback